A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2a Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Orally Administered TERN-101 Tablets in Adult Patients With Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)
Latest Information Update: 08 Aug 2023
At a glance
- Drugs TERN-101 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Acronyms LIFT
- Sponsors Terns Pharmaceuticals
Most Recent Events
- 24 Jun 2023 Results of pooled analysis from LIFT and AVIATION presented at the European Association for the Study of the Liver Congress 2023.
- 26 Jun 2022 The pharmacokinetic (PK) and pharma- codynamic (PD) results from the LIFT study presented at The International Liver Congress 2022
- 26 Jun 2022 Results presented at The International Liver Congress 2022